Zydus Lifesciences bags FDA tentative approval for Enzalutamide Tablets for prostate cancer treatment
Zydus Lifesciences Limited has secured tentative approval from the United States Food and Drug Administration (USFDA) for its Enzalutamide Tablets, available in 40 mg and ... Read More
Zydus Lifesciences launches fight against prostate cancer with new FDA-approved drug enzalutamide
Zydus Lifesciences Limited has achieved a significant milestone in the pharmaceutical industry. The company recently received final approval from the United States Food and Drug ... Read More
Game-changing cancer therapy: Imugene’s VAXINIA receives FDA orphan drug status for bile tract cancer
Imugene Limited has received a significant boost with the United States Food and Drug Administration (FDA) granting Orphan Drug Designation (ODD) to its experimental therapy, ... Read More